2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Carboplatin
159
Paclitaxel
153
Bevacizumab
85
Taxes
48
Gemcitabine
48
liposomal doxorubicin
47
Topotecan
41
Cisplatin
35
pembrolizumab
33
Cyclophosphamide
28
olaparib
25
Immunoglobulin G
24
Disulfides
24
Specimen Handling
21
Drug Therapy
20
Docetaxel
20
niraparib
18
Magnetic Resonance Spectroscopy
18
Doxorubicin
17
Biopsy
15
mirvetuximab soravtansine
14
Hyperthermic Intraperitoneal Chemotherapy
14
rucaparib
13
Nivolumab
12
Cytoreduction Surgical Procedures
11
Chemotherapy, Adjuvant
10
Albumin-Bound Paclitaxel
10
veliparib
9
Platinum
9
Neoadjuvant Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled